Contact information
Collaborators
-
Richard Hobbs
Mercian Professor of Primary Care
-
Rafael Perera
Director Medical Statistics and Director of Graduate Studies
-
James Sheppard
Professor of Applied Health Data Science
-
Brian D Nicholson
Associate Professor
Ting Cai
DPhil, MPH, BMed
NIHR ARC Research Fellow
Medical Statistics | Data Sciences | Dementia | Pharmacoepidemiology | Clinical Risk Prediction
Current position
Dr Ting Cai is a research fellow funded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) Oxford and Thames Valley. In this fellowship, she focuses on dementia research using pharmacoepidemiological approaches and large-scale healthcare databases to explore the potential medications for dementia prevention and treatment.
Alongside the fellowship, Dr Cai is also part of the Cancer Research Group, working on the BLOTTED project that aims to develop clinical prediction models incorporating blood test trends for risk of cancer to help identify patients who need referral for further investigation.
Research Interest
Dr Cai's primary research interest lies in the area of pharmacoepidemiology, especially evaluation of effectiveness and safety of pharmaceutical products (including drugs and vaccines) leveraging large-scale data from multiple sources, such as linked electronic healthcare records, national administration data, or population-based cohort data. She also has a continuing interest in clinical risk prediction modelling for disease diagnostic and prognostic research.
Dr Cai welcomes world-wide collaborations in these research areas and accepts requests for co-supervision of Oxford DPhil and MSc students in relevant areas.
Background and Expertise
Dr Cai has years of experience in pharmacoepidemiology (and broadly epidemiology), medical statistics, and evidence-based medicine, with expertise in statistical analysis for epidemiological causal inferences, risk prediction modelling for disease or treatment outcomes, and advanced meta-analysis of clinical trial data. She also has skills and experience in data management and statistical programming in large datasets.
Dr Cai was awarded a DPhil in Primary Care Health Sciences from University of Oxford and her study was funded by the British Heart Foundation (BHF). She also holds a Master of Public Health in Pharmacoepidemiology and a Bachelor of Medicine in Preventive Medicine.
Recent publications
Statin safety in prevention of cardiovascular diseases: causal inference and risk prediction
Thesis / Dissertation
Cai T., (2025)
How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analyses
Journal article
Abel L. et al, (2024), Health and Quality of Life Outcomes, 22
Physical activity for treatment of irritable bowel syndrome
Journal article
Nunan D. et al, (2022), Cochrane Database of Systematic Reviews, 2022
PREDICTING INDIVIDUAL RISK OF MUSCLE DISORDERS IN PATIENTS ELIGIBLE FOR STATIN TREATMENT: STRATIFY-STATINMD MODEL DERIVATION USING DATA FROM ELECTRONIC HEALTH RECORDS
Journal article
Cai T. et al, (2022), Journal of hypertension, 40, e76 - e77
Predicting individual risk of muscle disorders in patients eligible for statin treatment: Derivation and external validation of stratify-statinmd prediction model
Conference paper
Cai T. et al, (2022), PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 31, 285 - 285
Predicting individual risk of muscle disorders in patients eligible for statin treatment: derivation and validation of STRATIFY-StatinMD prediction model
Other
Cai T. et al, (2022), JOURNAL OF HUMAN HYPERTENSION, 36, 10 - 10
PREDICTING INDIVIDUAL RISK OF MUSCLE DISORDERS IN PATIENTS ELIGIBLE FOR STATIN TREATMENT: STRATIFY-STATINMD MODEL DERIVATION USING DATA FROM ELECTRONIC HEALTH RECORDS
Conference paper
Cai T. et al, (2022), JOURNAL OF HYPERTENSION, 40, E76 - E77
PREDICTING INDIVIDUAL RISK OF MUSCLE DISORDERS IN PATIENTS ELIGIBLE FOR STATIN TREATMENT: STRATIFY-STATINMD MODEL DERIVATION USING DATA FROM ELECTRONIC HEALTH RECORDS
Conference paper
Cai T. et al, (2022), JOURNAL OF HYPERTENSION, 40, E76 - E77
ssociations between statins and adverse events in primary prevention of cardiovascular disease: Systematic review with pairwise, network, and dose-response meta-analyses
Journal article
Cai T. et al, (2021), The BMJ, 374
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: A rapid review
Journal article
Dorward J. et al, (2021), Antiviral Therapy, 25, 365 - 376
ssociations between statins and adverse events in primary prevention of cardiovascular disease: a systematic review with meta-analysis
Other
Cai T. et al, (2021), JOURNAL OF HUMAN HYPERTENSION, 35, 11 - 12
Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.
Journal article
Yi Z-M. et al, (2019), Neuropsychiatr Dis Treat, 15, 1 - 19
The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis
Journal article
Wu S. et al, (2018), Expert Opinion on Drug Safety, 17, 243 - 249
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Journal article
Yang J. et al, (2017), PLoS One, 12